Thymic peptides restrain the inflammatory response in mice with experimental autoimmune encephalomyelitis.

Lunin SM, Glushkova OV, Khrenov MO, Novoselova TV, Parfenyuk SB, Fesenko EE, Novoselova EG

Immunobiology28 May 2012Cited by 16 (Europe PMC)

PMID22727332DOI10.1016/j.imbio.2012.05.023PepBankPUB-22727332

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin reduced disease severity compared with untreated EAE mice.
In plain wordsIn mice with EAE, thymulin reduced disease severity compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseDisease severity
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Immune response · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
1 context sentence(design, population, supporting numbers)
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Report a problemFND-2272733201
02AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin's therapeutic effect persisted after withdrawal.
In plain wordsIn mice with EAE, thymulin's effect continued after treatment stopped.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicablePersistence after withdrawal
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Immune response · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
The effect of thymulin but not thymopentin remained after its withdrawal.
2 context sentences(design, population, supporting numbers)
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Report a problemFND-2272733202
03AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin reduced the early-phase interferon-gamma response compared with untreated EAE mice.
In plain wordsIn mice with EAE, thymulin reduced early interferon-gamma responses compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
Decreaseearly-phase interferon-gamma response
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
Thymulin reduced the cytokine response in both the early and the delayed phases, whereas thymopentin only reduced the "early phase cytokines" (IL-6 and interferon-gamma).
3 context sentences(design, population, supporting numbers)
Summary · context
In the "early" phase, which started at day 35, increased levels of interferon-gamma and interleukin-6 in the blood were observed; during the "delayed" phase, which started at day 48, the levels of plasma interleukin-17 and tumour necrosis factor-alpha were also raised.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Report a problemFND-2272733203
04AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin reduced the delayed-phase interleukin-17 response compared with untreated EAE mice.
In plain wordsIn mice with EAE, thymulin reduced delayed interleukin-17 responses compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
Decreasedelayed-phase interleukin-17 response
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
Thymulin reduced the cytokine response in both the early and the delayed phases, whereas thymopentin only reduced the "early phase cytokines" (IL-6 and interferon-gamma).
3 context sentences(design, population, supporting numbers)
Summary · context
In the "early" phase, which started at day 35, increased levels of interferon-gamma and interleukin-6 in the blood were observed; during the "delayed" phase, which started at day 48, the levels of plasma interleukin-17 and tumour necrosis factor-alpha were also raised.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Report a problemFND-2272733204
05AnimalAnimal study (in vivo)Mechanism
In EAE mice, thymulin reduced IKK phosphorylation.
In plain wordsIn mice with EAE, thymulin reduced IKK phosphorylation compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseIKK phosphorylation
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Receptor activity and mechanism · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
Both peptides significantly reduced the level of phosphorylation of the NF-kappaB signalling protein IKK and the production of Hsp72 protein.
2 context sentences(design, population, supporting numbers)
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Report a problemFND-2272733205
06AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin reduced Hsp72 production.
In plain wordsIn mice with EAE, thymulin reduced Hsp72 production compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseHsp72 production
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
Both peptides significantly reduced the level of phosphorylation of the NF-kappaB signalling protein IKK and the production of Hsp72 protein.
2 context sentences(design, population, supporting numbers)
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Report a problemFND-2272733206
07AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin reduced the early-phase interleukin-6 response compared with untreated EAE mice.
In plain wordsIn mice with EAE, thymulin reduced early interleukin-6 responses compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
Decreaseearly-phase interleukin-6 response
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
Thymulin reduced the cytokine response in both the early and the delayed phases, whereas thymopentin only reduced the "early phase cytokines" (IL-6 and interferon-gamma).
3 context sentences(design, population, supporting numbers)
Summary · context
In the "early" phase, which started at day 35, increased levels of interferon-gamma and interleukin-6 in the blood were observed; during the "delayed" phase, which started at day 48, the levels of plasma interleukin-17 and tumour necrosis factor-alpha were also raised.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Report a problemFND-2272733207
08AnimalAnimal study (in vivo)Efficacy outcome
In EAE mice, thymulin reduced the delayed-phase tumour necrosis factor-alpha response compared with untreated EAE mice.
In plain wordsIn mice with EAE, thymulin reduced delayed tumour necrosis factor-alpha responses compared with untreated mice.
Peptide
Thymulin (serum thymic factor)
Outcome
Decreasedelayed-phase tumour necrosis factor-alpha response
Study
mousen: not reported in source
NZW mice with EAE
Comparator
Untreated EAE mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 μg per 100g of body weight · intraperitoneal · 30 daysAs given in this study (mouse).
Source sentences
Summary
Thymulin reduced the cytokine response in both the early and the delayed phases, whereas thymopentin only reduced the "early phase cytokines" (IL-6 and interferon-gamma).
3 context sentences(design, population, supporting numbers)
Summary · context
In the "early" phase, which started at day 35, increased levels of interferon-gamma and interleukin-6 in the blood were observed; during the "delayed" phase, which started at day 48, the levels of plasma interleukin-17 and tumour necrosis factor-alpha were also raised.
Summary · context
When applied intraperitoneally every other day for 30 days, either thymulin or thymopentin (15 μg per 100g of body weight) significantly reduced the disease severity compared to untreated EAE mice.
Summary · context
EAE was induced in NZW mice by a single immunisation with myelin basic protein coupled with adjuvants.
Report a problemFND-2272733208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 2
21 Oct 2026, 13:55 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.